Benzinga | Dec 17, 2021 10:27AM EST

Oppenheimer Maintains Outperform on Medtronic, Lowers Price Target to $136

Oppenheimer analyst Steven Lichtman maintains Medtronic (NYSE:MDT) with a Outperform and lowers the price target from $145 to $136.